Bradley James Runyon, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 830 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-9822 Fax: 269-781-9839 |
Joanna M Deluco, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 14915 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-9863 Fax: 269-781-9864 |
Dr. Joseph M Hibler, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 15865 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-6644 Fax: 269-781-0130 |
Dr. Naiya Panchal, O.D Optometrist Medicare: Accepting Medicare Assignments Practice Location: 830 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-9822 Fax: 269-781-3622 |
Dr. James E Fletcher, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 14915 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-9863 |
Dr. Patricia M Woznicki, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 830 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-9822 Fax: 269-781-9839 |
Joseph M Hibler Od Pc Inc Optometrist Medicare: Medicare Enrolled Practice Location: 15865 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-6644 Fax: 269-781-0130 |
Marshall Eye Care P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 14915 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-9863 |
Matthew James Huberty, OD Optometrist Medicare: Medicare Enrolled Practice Location: 14915 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-9863 |
Marshall Eye Care Optometrist Medicare: Medicare Enrolled Practice Location: 14915 W Michigan Ave, Marshall, MI 49068 Phone: 269-781-9863 Fax: 269-781-8964 |
News Archive
Patient-reported experiences have potential for driving improvements in the quality of hospital care, according to a new study in the Canadian Journal of Cardiology, published by Elsevier.
Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome.
Scientists at The Wistar Institute have demonstrated how a protein called TRAP1 - an important regulator of energy production in healthy and cancerous cells - is an important driver of prostate cancer and appears to be a valuable therapeutic target for the disease.
Fero Industries, Inc. is pleased to announce that it has contracted PNP Pharmaceuticals Inc. as the exclusive global manufacturer of SucanonĀ®, an oral treatment for type-2 diabetes.
Researchers in the College of Arts and Sciences have determined that cannabinoid drugs do not appear to reduce the intensity of experimental pain, but, instead, may make pain feel less unpleasant and more tolerable.
› Verified 4 days ago